

Supplemental Application Data Sheet 37 CFR 1.76	Attorney Docket Number	CELL-0311
	Application Number	10/560,119
Title of Invention Hydroxamate Sulfonamides as CD23 Shedding Inhibitors		
<p>The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76.</p> <p>This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.</p>		

Secrecy Order 37 CFR 5.2

<input type="checkbox"/>	Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
--------------------------	---

Applicant Information:

Applicant 1				
Applicant Authority <input checked="" type="checkbox"/> Inventor		<input type="checkbox"/> Legal Representative under 35 U.S.C. 117		<input type="checkbox"/> Party of Interest under 35 U.S.C. 118
Prefix	Given Name	Middle Name	Family Name	Suffix
	David	Alan	Owen	
Residence Information (Select One) <input type="checkbox"/> US Residency <input checked="" type="checkbox"/> Non US Residency <input type="checkbox"/> Active US Military Service				
City	Milton, Cambridge	State/Province		Country of Residence ⁱ GB
Citizenship under 37 CFR 1.41 (b) ⁱ		GB		
Mailing Address of Applicant:				
Address 1		c/o Celltech R&D Limited, 208 Bath Road		
Address 2				
City	Slough, Berkshire	State/Province		
Postal Code	SL1 3WE	Country ⁱ	GB	
Applicant 2				
Applicant Authority <input checked="" type="checkbox"/> Inventor		<input type="checkbox"/> Legal Representative under 35 U.S.C. 117		<input type="checkbox"/> Party of Interest under 35 U.S.C. 118
Prefix	Given Name	Middle Name	Family Name	Suffix
	Robert	John	Watson	
Residence Information (Select One) <input type="checkbox"/> US Residency <input checked="" type="checkbox"/> Non US Residency <input type="checkbox"/> Active US Military Service				
City	Hauxton, Cambridge	State/Province		Country of Residence ⁱ GB
Citizenship under 37 CFR 1.41 (b) ⁱ		GB		
Mailing Address of Applicant:				
Address 1		c/o Celltech R&D Limited, 208 Bath Road		
Address 2				
City	Slough, Berkshire	State/Province		
Postal Code	SL1 3WE	Country ⁱ	GB	
Applicant 3				
Applicant Authority <input checked="" type="checkbox"/> Inventor		<input type="checkbox"/> Legal Representative under 35 U.S.C. 117		<input type="checkbox"/> Party of Interest under 35 U.S.C. 118
Prefix	Given Name	Middle Name	Family Name	Suffix
	Daniel	Rees	Allen	
Residence Information (Select One) <input type="checkbox"/> US Residency <input checked="" type="checkbox"/> Non US Residency <input type="checkbox"/> Active US Military Service				

Supplemental Application Data Sheet 37 CFR 1.76	Attorney Docket Number	CELL-0311
	Application Number	10/560,119
Title of Invention Hydroxamate Sulfonamides as CD23 Shedding Inhibitors		

City	Cambridge	State/Province		Country of Residence ⁱ	GB
Citizenship under 37 CFR 1.41 (b) ⁱ GB					
Mailing Address of Applicant:					
Address 1		c/o Celltech R&D Limited, 208 Bath Road			
Address 2					
City	Slough, Berkshire	State/Province			
Postal Code	SL1 3WE	Country ⁱ	GB		

Applicant 4				
Applicant Authority <input checked="" type="checkbox"/> Inventor <input type="checkbox"/> Legal Representative under 35 U.S.C. 117 <input type="checkbox"/> Party of Interest under 35 U.S.C. 118				
Prefix	Given Name	Middle Name	Family Name	Suffix
	Andrew		Sharpe	

Residence Information (Select One) <input type="checkbox"/> US Residency <input checked="" type="checkbox"/> Non US Residency <input type="checkbox"/> Active US Military Service				
City	Cambridge	State/Province		Country of Residence ⁱ GB
Citizenship under 37 CFR 1.41 (b) ⁱ GB				

Mailing Address of Applicant:				
Address 1		c/o Celltech R&D Limited, 208 Bath Road		
Address 2				
City	Slough, Berkshire	State/Province		
Postal Code	SL1 3WE	Country ⁱ	GB	

Applicant 5				
Applicant Authority <input checked="" type="checkbox"/> Inventor <input type="checkbox"/> Legal Representative under 35 U.S.C. 117 <input type="checkbox"/> Party of Interest under 35 U.S.C. 118				
Prefix	Given Name	Middle Name	Family Name	Suffix
	Hazel	Joan	Dyke	

Residence Information (Select One) <input type="checkbox"/> US Residency <input checked="" type="checkbox"/> Non US Residency <input type="checkbox"/> Active US Military Service				
City	Safron, Walden	State/Province		Country of Residence ⁱ GB
Citizenship under 37 CFR 1.41 (b) ⁱ GB				

Mailing Address of Applicant:				
Address 1		c/o Celltech R&D Limited, 208 Bath Road		
Address 2				
City	Slough, Berkshire	State/Province		
Postal Code	SL1 3WE	Country ⁱ	GB	

All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the **Add** button.

Supplemental Application Data Sheet 37 CFR 1.76	Attorney Docket Number	CELL-0311
	Application Number	10/560,119
Title of Invention	Hydroxamate Sulfonamides as CD23 Shedding Inhibitors	

Correspondence Information:

Enter either Customer Number or complete the Correspondence Information section below.
For further information see 37 CFR 1.33(a).

☐ An Address is being provided for the correspondence information of this application.

Customer Number	23377
Email Address	

Application Information:

Title of the Invention	Hydroxamate Sulfonamides as CD23 Shedding Inhibitors		
Attorney Docket Number	CELL-0311	Small Entity Status Claimed <input type="checkbox"/>	
Application Type	NonProvisional		
Subject Matter	Utility		
Suggested Class (if any)		Sub Class (if any)	
Suggested Technology Center (if any)			
Total Number of Drawing Sheets (if any)		Suggested Figure for Publication (if any)	

Supplemental Application Data Sheet 37 CFR 1.76		Attorney Docket Number	CELL-0311
		Application Number	10/560,119
Title of Invention	Hydroxamate Sulfonamides as CD23 Shedding Inhibitors		

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)

☐ **Request Not to Publish.** I hereby request that the attached application **has not been and will not be** the subject of an application filed in another country, or under a multilateral agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Enter either Customer Number or complete the Representative Name section below. If both sections are completed the Customer Number will be used for the Representative Information during processing.

Please Select One: ☒ Customer Number ☐ US Patent Practitioner ☐ US Representative (37 CFR 11.9)

Customer Number 23377

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, or 365(c) or indicate National Stage entry from a PCT application. Providing this information in the application data sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78(a)(2) or CFR 1.78(a)(4), and need not otherwise be made part of the specification.

Prior Application Status	Expired		
Application Number	Continuity Type	Prior Application Number	Filing Date (YYYY-MM-DD)
10/560,119	a 371 of international	PCT/GB/2004/002638	2004-06-18
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the Add button.			

Foreign Priority Information:

This section allows for the applicant to claim benefit of foreign priority and to identify any prior foreign application for which priority is not claimed. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55(a).

Application Number	Country ¹	Parent Filing Date (YYYY-MM-DD)	Priority Claimed
[0314246.0] <u>0314244.5</u>	GB	2003-06-19	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Application Number	Country ¹	Parent Filing Date (YYYY-MM-DD)	Priority Claimed
[0325832.4] <u>0325834.0</u>	GB	2003-11-05	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Additional Foreign Priority Data may be generated within this form by selecting the Add button.			

Supplemental Application Data Sheet 37 CFR 1.76		Attorney Docket Number	CELL-0311
		Application Number	10/560,119
Title of Invention	Hydroxamate Sulfonamides as CD23 Shedding Inhibitors		

Assignee Information:

Providing this information in the application data sheet does not substitute for compliance with any requirement of part 3 of Title 37 of the CFR to have an assignment recorded in the Office.			
Assignee 1			
If the Assignee is an Organization check here. <input checked="" type="checkbox"/>			
Organization Name:		Celltech R&D Limited	
Mailing Address Information:			
Address 1		208 Bath Raod	
Address 2			
City	Slough, Berkshire	State/Province	
Country	GB	Postal Code	SL1 3WE
Phone Number		Fax Number	
Email Address			
Additional Assignee Data may be generated within this form by selecting the Add button.			

Signature:

A signature of the applicant or representative is required in accordance with 37 CFR 1.33 and 10.18. Please see 37 CFR 1.4(d) for the form of the signature.					
Signature	/Marcia Ireland Rosenfeld/		Date (YYYY-MM-DD)	2007-12-05	
First Name	Marcia	Last Name	Ireland Rosenfeld	Registration Number	60,679

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**